Roivant Sciences Ltd. (ROIV)
NASDAQ: ROIV · Real-Time Price · USD
21.11
-0.54 (-2.49%)
Feb 5, 2026, 3:40 PM EST - Market open
Roivant Sciences Employees
Roivant Sciences had 750 employees as of March 31, 2025. The number of employees decreased by 158 or -17.40% compared to the previous year.
Employees
750
Change (1Y)
-158
Growth (1Y)
-17.40%
Revenue / Employee
$27,105
Profits / Employee
-$498,624
Market Cap
14.68B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2025 | 750 | -158 | -17.40% |
| Mar 31, 2024 | 908 | 4 | 0.44% |
| Mar 31, 2023 | 904 | 41 | 4.75% |
| Mar 31, 2022 | 863 | 198 | 29.77% |
| Jun 30, 2021 | 665 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Moderna | 5,800 |
| BioMarin Pharmaceutical | 3,040 |
| Genmab | 2,681 |
| Incyte | 2,617 |
| Exelixis | 1,147 |
| Ionis Pharmaceuticals | 1,069 |
| Ascendis Pharma | 1,017 |
| Revolution Medicines | 809 |
ROIV News
- 12 days ago - Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026 - GlobeNewsWire
- 23 days ago - Roivant Sciences Ltd. (ROIV) Presents at 44th Annual J.P. - Seeking Alpha
- 4 weeks ago - Roivant Sciences Ltd. (ROIV) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Goldman Sachs Mid Cap Growth Fund Q3 2025 Investment Update - Seeking Alpha
- 7 weeks ago - Roivant Sciences Ltd. (ROIV) Analyst/Investor Day Transcript - Seeking Alpha
- 2 months ago - Roivant Highlights Continued Pipeline Progress and Outlook for Company's Next Phase of Growth at 2025 Investor Day - GlobeNewsWire
- 2 months ago - Roivant Sciences Ltd. (ROIV) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha
- 3 months ago - Roivant Sciences: Brepocitinib And Roadmap Still Underpriced - Seeking Alpha